Why did ALTHX.PA stock jump today?

ALTHX.PA stock rose on 28 Jan 2026 due to heavy intraday volume and renewed interest after comparative performance charts circulated. In small-cap biotech, speculative flows and sector attention often trigger sharp moves rather than immediate fundamental changes.

What is Meyka AI’s price outlook for ALTHX.PA stock?

Meyka AI's model projects **€3.61** in 12 months and **€2.77** at three months. Versus today’s **€2.45**, that implies potential upside, but these are model-based projections and not guarantees.

What are the main risks to ALTHX.PA stock investors should watch?

Key risks include clinical trial failures, tight liquidity (market cap **€21196667.00**) and negative cash flow metrics. News-driven volatility is high for this clinical-stage company, so monitor trial calendars and cash-runway updates.

Is ALTHX.PA stock a buy after the 19.51% move?

After the rise, Meyka AI assigns a **B / HOLD** grade reflecting mixed fundamentals and upside potential. Investors should weigh trial-readout timing, cash runway, and personal risk tolerance before increasing exposure.

EU Stocks

ALTHX.PA stock +19.51% to €2.45 on EURONEXT 28 Jan 2026: volume spike

ByDanny Kontos January 29, 2026January 29, 2026

ALTHX.PA stock jumped 19.51% to €2.45 on EURONEXT at market close on 28 Jan 2026. Trading volume surged to 502039.00 shares versus an average of 89510.00, signaling strong intraday buying pressure. The move pushed the share price above its 50-day average of €1.96 and 200-day average of €1.76, attracting momentum traders in Europe’s healthcare segment. Meyka AI’s real-time screens flagged ALTHX.PA stock as a top gainer and flagged a mix of speculative flows and improving technicals as drivers for the jump.